Author

Mike Gart

Observed institutions: Integra (United States), Connect

OpenAlex ID: A5082874612

Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data

2023 · Jeffrey A. Scott, Jochen Lennerz, et al. · JCO Oncology Practice · 64

PDF

Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices.

2024 · Jing-Zhou Hou, Simon Blanc, et al. · Journal of Clinical Oncology · 4

Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study.

2022 · Robert E. Smith, Melissa Lynne Johnson, et al. · Journal of Clinical Oncology · 4

Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.

2023 · Anupama Vasudevan, Sandy English, et al. · Journal of Clinical Oncology · 3

Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study.

2022 · Mike Gart, Lucio N. Gordan, et al. · Journal of Clinical Oncology · 3

Abstract P1-11-21: Dose Reduction Impacts Persistence on Abemaciclib: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database

2025 · Vikram Gorantla, Rushir Choski, et al. · Clinical Cancer Research · 1

Validation of metastatic breast cancer (mBC) diagnosis in structured electronic health record (EHR) data vs chart-curated verification using the IntegraConnect Precision-Q (IC PQ) de-identified database.

2025 · Anna Rui, Samantha Eiffert, et al. · Journal of Clinical Oncology · 1

PDF

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

2024 · Jing-Zhou Hou, Rushir Choksi, et al. · Blood · 1

Abstract PO2-18-01: Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT)

2024 · Vikram Gorantla, Erin Alwon, et al. · Cancer Research · 1

HRR testing and PARPi utilization among patients with metastatic castration resistant prostate cancer treated in the real-world setting.

2024 · Anupama Vasudevan, Harvey I. Katzen, et al. · Journal of Clinical Oncology · 1

PDF

Comparison of molecular testing rates and biomarker positivity by histology among patients (pts) with stage IV non-small cell lung cancer (NSCLC): A quality initiative by Integra Connect PrecisionQ.

2023 · Simon Blanc, Mike Gart, et al. · JCO Oncology Practice · 1

PDF

PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer.

2023 · Fred J. Kudrik, Anupama Vasudevan, et al. · Journal of Clinical Oncology · 1

Understanding differences in the rates of BRCA/HRD testing and treatment in 1st line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ.

2023 · Fred J. Kudrik, Mike Gart, et al. · Journal of Clinical Oncology · 1

Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).

2023 · Arthur Sillah, Gboyega Adeboyeje, et al. · Journal of Clinical Oncology · 1

Hsd86 First-line Systemic Treatment Patterns in Metastatic Urothelial Carcinoma in Us Community Oncology Practices

2026 · Dhaval Shah, Asit Paul, et al. · Value in Health

Hsd88 Real-world Ros1 Testing in First-line Non-small Cell Lung Cancer

2026 · Raja Mudad, Rushir Choksi, et al. · Value in Health

Real-world ARPI utilization patterns and outcomes in metastatic castration-sensitive prostate cancer.

2026 · Manish Kohli, Jonathan David Tward, et al. · Journal of Clinical Oncology

PDF

Real-world time to next treatment in metastatic urothelial cancer patients: Enfortumab vedotin and pembrolizumab vs chemotherapy as first-line treatment.

2026 · Dhaval Shah, Deepak Kilari, et al. · Journal of Clinical Oncology

Clinical outcomes in the real-world utilization of 177Lu-PSMA 617 in metastatic castrate-resistant prostate cancer.

2026 · Manish Kohli, Jonathan David Tward, et al. · Journal of Clinical Oncology

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

2025 · Joseph Franz, Dhaval Mehta, et al. · Blood

PDF

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

2025 · Jing-Zhou Hou, Rushir Choksi, et al. · Blood

PDF

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

2025 · Jing-Zhou Hou, Tejvir Singh, et al. · Blood

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

2025 · Rushir Choksi, Aliakbar Dadla, et al. · Blood

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

2025 · Taral Patel, Rushir Choksi, et al. · Blood

PDF

Abstract P2-12-15: Trends in Antiemetic Use in Patients Receiving Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer: A Retrospective Analysis of Data from the IntegraConnect PrecisionQ De-Identified Database

2025 · Stephan Rosenfeld, Vikram Gorantla, et al. · Clinical Cancer Research

Works count: 55

Citation count: 87

H-index: 3

I10-index: 1